Federal Supply Schedule 36F79720D0169
Award Date
7/15/20
Last Date to Order
7/14/26
Federal Agency
Veterans Integrated Service Network 12
Awardee
Sobi, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The U.S. Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Sobi, Inc., a foreign-owned, for-profit pharmaceutical company, to provide the drugs TEGSEDI and ORFADIN. The BPA, valued up to $11.75 million, covers the period from October 2021 through September 2025. Sobi, Inc. also holds a multiple award schedule contract with the VA valued at up to $78 million through July 2025 for pharmaceutical products under the Federal...
The Department of Veterans Affairs (VA) awarded a Federal Supply Schedule (FSS) contract, valued at up to $3.5 million, to Calliditas Therapeutics US Inc., a foreign-owned, for-profit pharmaceutical company. The contract, under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, facilitates the procurement of TARPEYO, an innovative treatment for uncontrolled protein in urine due to primary immunoglobulin A nephropathy, a serious renal condition impacting some veterans. In addition to the FSS...
The U.S. Department of Veterans Affairs (VA) awarded a Federal Supply Schedule (FSS) contract to Takeda Pharmaceuticals America Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited. The contract, valued at $719,535,960, provides Takeda with a vehicle to supply a range of critical specialty pharmaceutical products to various VA facilities, Department of Justice Bureau of Prisons locations, and other federal agencies. Takeda, as the prime contractor,...
The Department of Veterans Affairs (VA) has awarded Chiesi USA Inc., a foreign-owned for-profit pharmaceutical company, an Indefinite Delivery/Indefinite Quantity (ID/IQ) Federal Supply Schedule (FSS) contract valued at up to $27.7 million for Pharmaceuticals and Drugs (FSS-61-IB). Under this contract, the VA has issued multiple firm fixed price delivery orders to Chiesi USA Inc. for the supply of deferiprone tablets in 1,000 mg doses to VA networks and facilities, including VISN 5, VISN 12, and...
The Department of Veterans Affairs (VA) awarded a 5-year, $5 million Federal Supply Schedule (FSS) contract under Schedule 65 I B for drugs, pharmaceuticals, and hematology-related products to Provention Bio Inc., a biopharmaceutical company. This FSS contract, awarded by the VA's VISN 12 in July 2023, allows the VA to procure Provention Bio's pharmaceutical products, including TZIELD, to support VA healthcare programs serving veterans. Additionally, the VA National Acquisition Center awarded...
The Department of Veterans Affairs (VA) Veterans Health Administration awarded Lundbeck LLC a 5-year Federal Supply Schedule contract (FSS-61-IB) for Pharmaceuticals and Drugs with a potential value of $124 million. Through this contract vehicle, the VA and other federal agencies can procure Lundbeck's portfolio of medications used to treat neurological conditions prevalent among veterans, including Sabril (vigabatrin) for treatment-resistant seizures, Xenazine (tetrabenazine) for chorea...
The U.S. Department of Veterans Affairs (VA) awarded Recordati Rare Diseases Inc., a foreign-owned pharmaceutical manufacturer, a $15.6 million multiple-award Federal Supply Schedule (FSS-61-IB) contract and a $3.1 million single-award Blanket Purchase Agreement to supply specialized orphan drugs and rare disease treatments. The contract vehicles allow the VA to efficiently procure Recordati's portfolio of medications, including Signifor LAR, Carbaglu, Cystadane, Isturisa, and Cystadrops,...
The Department of Veterans Affairs awarded a multiple-award Federal Supply Schedule contract to Viela Bio, Inc. against the Pharmaceuticals and Drugs schedule for an estimated $12.98 million. This IDV establishes supply of pharmaceutical products to various VA medical centers nationwide through 2022. A single-award Blanket Purchase Agreement against the same FSS schedule was also awarded to Viela Bio for an estimated $4.35 million. This BPA facilitates streamlined delivery of the neuromyelitis...
The U.S. Department of Veterans Affairs (VA) has awarded a Blanket Purchase Agreement (BPA) contract to Calliditas Therapeutics US Inc., a foreign-owned, for-profit pharmaceutical company, to provide the medication TARPEYO. This BPA, valued at $1,750,000 and running through April 2026, designates Calliditas Therapeutics US Inc. as the sole approved supplier of TARPEYO to VA medical facilities nationwide. TARPEYO is an innovative treatment for uncontrolled protein in the urine due to primary...
The U.S. Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit manufacturer of pharmaceutical products, under the company's General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs. The single-award BPA, valued at over $13 million, is for the supply of the oncology medication ICLUSIG (ponatinib) to various VA Medical Centers and Veterans Integrated Service Networks (VISNs)...